Page 90 - 中国药房2023年10期

[ 7 ] MITSUDOMI T，MORITA S，YATABE Y，et al. Gefitinib 华肿瘤杂志，2023，45（1）：31-38.
versus cisplatin plus docetaxel in patients with non-small- [17] RANSON M，HAMMOND L A，FERRY D，et al.
cell lung cancer harbouring mutations of the epidermal ZD1839，a selective oral epidermal growth factor receptor
growth factor receptor（WJTOG3405）：an open label，ran‐ tyrosine kinase inhibitor，is well tolerated and active in
domised phase 3 trial[J]. Lancet Oncol，2010，11（2）： patients with solid，malignant tumors：results of a phase
121-128. Ⅰ trial[J]. J Clin Oncol，2002，20（9）：2240-2250.
[ 8 ] XIE H N，WANG H，XU L，et al. Gefitinib versus adju‐ [18] CHENG Y，MURAKAMI H，YANG P C，et al. Ran-
vant chemotherapy in patients with stage Ⅱ - Ⅲ A non- domized phase Ⅱ trial of gefitinib with and without peme‐
small-cell lung cancer harboring positive EGFR muta‐ trexed as first-line therapy in patients with advanced non‐
tions：a single-center retrospective study[J]. Clin Lung squamous non-small-cell lung cancer with activating
Cancer，2018，19（6）：484-492. epidermal growth factor receptor mutations[J]. J Clin
[ 9 ] DAI L L，WANG W，LI W L，et al. Effect of gefitinib Oncol，2016，34（27）：3258-3266.
combined with chemotherapy in patients with advanced [19] NORONHA V，PATIL V M，JOSHI A，et al. Gefitinib
NSCLC：a retrospective cohort study[J]. Int J Gen Med， versus gefitinib plus pemetrexed and carboplatin chemo‐
2022，15：637-644. therapy in EGFR-mutated lung cancer[J]. J Clin Oncol，
[10] TAN F L，SHEN X Y，WANG D C，et al. Icotinib（BPI- 2020，38（2）：124-136.
2009H），a novel EGFR tyrosine kinase inhibitor，displays [20] HOU X，LI M C，WU G W，et al. Gefitinib plus chemo‐
potent efficacy in preclinical studies[J]. Lung Cancer， therapy vs gefitinib alone in untreated EGFR-mutant non-
2012，76（2）：177-182. small cell lung cancer in patients with brain metastases：
[11] SHI Y K，ZHANG L，LIU X Q，et al. Icotinib versus the GAP BRAIN open-label，randomized，multicenter，
gefitinib in previously treated advanced non-small-cell phase 3 study[J]. JAMA Netw Open，2023，6（2）：
lung cancer（ICOGEN）：a randomised，double-blind phase e2255050.
3 non-inferiority trial[J]. Lancet Oncol，2013，14（10）： [21] SHI Y K，WANG L，HAN B H，et al. First-line icotinib
953-961. versus cisplatin/pemetrexed plus pemetrexed maintenance
[12] EISENHAUER E A，THERASSE P，BOGAERTS J，et al. therapy for patients with advanced EGFR mutation-
New response evaluation criteria in solid tumours：revised positive lung adenocarcinoma（CONVINCE）：a phase 3，
RECIST guideline（version 1.1）[J]. Eur J Cancer，2009，45 open-label，randomized study[J]. Ann Oncol，2017，28
（2）：228-247. （10）：2443-2450.
[13] CHEN AP，SETSER A，ANADKAT M J，et al. Grading [22] WU Y L，CHENG Y，ZHOU X D，et al. Dacomitinib
dermatologic adverse events of cancer treatments：the versus gefitinib as first-line treatment for patients with
Common Terminology Criteria for Adverse Events Version EGFR-mutation-positive non-small-cell lung cancer（ARCHER
4.0[J]. J Am Acad Dermatol，2012，67（5）：1025-1039. 1050）：a randomised，open-label，phase 3 trial[J]. Lancet
[14] TAN F L，SHI Y K，WANG Y X，et al. Icotinib，a selective Oncol，2017，18（11）：1454-1466.
EGF receptor tyrosine kinase inhibitor，for the treatment [23] WU Y L，TSUBOI M，HE J，et al. Osimertinib in resected
of non-small-cell lung cancer[J]. Future Oncol，2015，11 EGFR-mutated non-small-cell lung cancer[J]. N Engl J
（3）：385-397. Med，2020，383（18）：1711-1723.
[15] HE J X，SU C X，LIANG W H，et al. Icotinib versus [24] SEQUIST L V，YANG J C，YAMAMOTO N，et al. Phase
chemotherapy as adjuvant treatment for stage Ⅱ - Ⅲ A Ⅲ study of afatinib or cisplatin plus pemetrexed in
EGFR-mutant non-small-cell lung cancer（EVIDENCE）： patients with metastatic lung adenocarcinoma with EGFR
a randomised，open-label，phase 3 trial[J]. Lancet Respir mutations[J]. J Clin Oncol，2013，31（27）：3327-3334.
Med，2021，9（9）：1021-1029. （收稿日期：2022-11-28 修回日期：2023-03-07）
[16] 中国医疗保健国际交流促进会，广东省胸部疾病学会 . （编辑：陈 宏）
埃克替尼术后辅助治疗非小细胞肺癌的专家共识[J]. 中

· 1232 · China Pharmacy 2023 Vol. 34 No. 10 中国药房 2023年第34卷第10期